Novimmune Sa

Novimmunie S.a.

Novlmmune S.a.

Pierre Fabre Medicament

Olivier Leger

Greg Elson

Marie Kosco-Vilbois

Nicolas Fischer

Walter Ferlin

Florence Guilhot

Bernard Francois Mach

Yann Dean

Krzysztof Masternak

Liliane Goetsch

Nathalie Corvaia

Greg Christopher Andrew Elson

Laurent Chevalet

Alain Vicari

Eugene Zhukovsky

Richard J Morse

Greg Christopher Elson

Amanda Ei Proudfoot

Joost Alexander Kolkman

Michael John Saunders

This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Anti-IL-6/IL-6R antibodies and methods of use thereof

This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.

Neutralizing antibodies and methods of use thereof

The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Anti-CD3 antibodies and methods of use thereof

Anti-IL-6/IL-6R antibodies

Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

Fc receptor-binding polypeptides with modified effector functions

The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFN&#x3b3;), thereby modulating the interaction between IFN&#x3b3; and its receptor, IFN&#x3b3;-R, and/or modulating the biological activities of IFN&#x3b3;. The invention also relates to the use of such anti-IFN&#x3b3; antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.

Anti-interferon gamma antibodies and methods of use thereof

This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies

This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.

Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodies

Methods of treatment using anti-IL-17A/IL-17F cross-reactive antibodies

Anti-IL-17A/IL-17F cross-reactive antibodies

Growing community of inventors

St. Sixt, France

Olivier Leger